What does this research mean for the field?

Cardiac amyloidosis is underdiagnosed, with an average diagnosis time of 2 years after the first symptoms. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to enhance the understanding and diagnostic approach to cardiac amyloidosis subtypes using various methods of analysis.

February 2, 2026Open Access

Bridging the Gap in AL and ATTR Cardiac Amyloidosis: Integrating Histopathology, Biomarkers, and Multimodal Imaging for Subtype-Specific Diagnosis

Q: What is the clinical evidence from this study?

Study design: Other. Population: cardiac amyloidosis. Primary outcome: mean time from first symptoms to a diagnosis of cardiac amyloidosis.

Key Result

Cardiac amyloidosis is underdiagnosed, with an average diagnosis time of 2 years after the first symptoms.

Key Points

This research aims to enhance the understanding and diagnostic approach to cardiac amyloidosis subtypes using various methods of analysis.
Review of contemporary literature on cardiac amyloidosis
Analysis of histopathology and biomarker technologies
Discussion of advanced imaging techniques
Comparison of subtype-specific mechanisms and diagnostic strategies
Increased understanding of molecular mechanisms behind cardiac amyloidosis
Improved diagnostic precision through multimodal approaches
Identification of sex- and ethnicity-based diagnostic disparities
Recognition of the phenotypic variability in disease presentation

PICO

Population

cardiac amyloidosis

Primary Outcome

mean time from first symptoms to a diagnosis of cardiac amyloidosis

Limitations

The study is a review, rather than a clinical trial, thus lacking primary clinical trial data.

Abstract

Cardiac amyloidosis (CA) represents an increasingly recognized but historically underdiagnosed cause of restrictive cardiomyopathy and heart failure. CA is now understood to be more prevalent, particularly in older adults, as advancements in imaging and biomarker technologies have improved detection. The disease results from the misfolding of precursor proteins, primarily immunoglobulin light chains (in light chain (AL) amyloidosis) or transthyretin (in transthyretin (ATTR) amyloidosis), into insoluble fibrils that deposit in myocardial tissue. These deposits cause structural and functional cardiac impairment through both physical infiltration and cytotoxic mechanisms, leading to diastolic dysfunction, arrhythmias, and progressive heart failure. Understanding the molecular basis of amyloid formation and deposition has revealed subtype-specific mechanisms of toxicity and tissue tropism, highlighting the central role of protein instability, proteolytic cleavage, and oxidative stress in disease progression. Furthermore, increasing awareness of phenotypic variability and sex- or ethnicity-based diagnostic disparities has called for earlier recognition and differentiation of CA subtypes. Diagnostic precision is enhanced by a multimodal approach incorporating histopathology, biomarker staging, and advanced imaging techniques such as echocardiography, cardiac magnetic resonance, and nuclear scintigraphy. This review addresses our contemporary understanding of the molecular mechanisms, pathophysiologic cascade, and diagnostic evolution of AL and ATTR CA, emphasizing clinical progress. By delineating the biological mechanisms and tools for early identification, this paper aims to strengthen the framework for diagnosing and managing a disease that was once overlooked but is now at the forefront of modern cardiovascular medicine.

Bookmark

View Full Paper